Chong Kun Dang Pharmaceutical Corp. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of fibrosis, neurodegeneration, nutrition, endocrine, immunological, inflammatory, psychiatric and renal disorders, among others.
Aligos Therapeutics Inc. has patented programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.
Researchers from Cyclone Therapeutics Inc. and the Scripps Research Institute have disclosed tetracycline derivatives reported to be useful for the treatment of fragile X syndrome, rheumatoid arthritis and Alzheimer’s disease.
Researchers from the Institute of Medicinal Biotechnology in China reported the preclinical characterization of a series of benzene sulfonamide derivatives developed as androgen receptor (AR) antagonists.
Researchers from the University of California, Davis have designed a novel gene therapy vector that selectively targets and kills cells infected with Kaposi’s sarcoma-associated herpesvirus (KSHV).
Mutations that activate phosphorylation of certain Rab GTPases by LRRK2 have been linked to a subset of genetic cases of Parkinson’s disease, and PPM1M is one of the phosphatases responsible for reversing phosphorylation by LRRK2.
Researchers at Sanofi SA have developed a promising gene therapy approach targeting the microtubule-associated protein tau (MAPT) for the treatment of Alzheimer’s disease.
HCW Biologics Inc. has developed second-generation, tissue factor-targeting T-cell engagers (TCEs) to treat solid tumors, particularly pancreatic cancer and glioblastoma, constructed with its novel proprietary TRBC product discovery and development platform technology.
RSS
